First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

Autor: Peters, S., Scherpereel, A., Cornelissen, R., Oulkhouir, Y., Greillier, L., Kaplan, M.A., Talbot, T., Monnet, I., Hiret, S., Baas, P., Nowak, A.K., Fujimoto, N., Tsao, A.S., Mansfield, A.S., Popat, S., Zhang, X., Hu, N., Balli, D., Spires, T., Zalcman, G.

Publikováno v: Annals of Oncology
Annals of Oncology, 2022, 33 (5), pp.488-499. ⟨10.1016/j.annonc.2022.01.074⟩
Annals of Oncology, 33(5), 488-499. ELSEVIER
Annals of Oncology, 33(5), 488-499. Elsevier Ltd.

International audience; Background: In the phase III CheckMate 743 study (NCT02899299), first-line nivolumab plus ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with unresectable malignant pleural mesothelioma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4255710dc1654fd9d6b202fe1d21a85
https://doi.org/10.1016/j.annonc.2022.01.074

1307P Clinical characteristics and therapeutic sequences of KRAS G12C advanced non-small cell lung cancer (aNSCLC) patients (pts) treated by sotorasib in the French post-marketing authorization early access (post-MA EA)

Autor: Cadranel, J., Curcio, H., Oulkhouir, Y., Couraud, S., Gille, R., Mazieres, J., Métivier, A-C., Girard, N., Wislez, M., Guisier, F., Almotlak, H., Quantin, X., Bardel, C., Naltet, C., Madroszyk Flandin, A-C., Roch, B., Greillier, L., Clément, C., De Gunten, L., Gounant, V.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S831-S832

RADIORYTHMIC: Phase III, Opened, Randomized Study of Postoperative Radiotherapy Versus Surveillance in Stage IIb/III of Masaoka Koga Thymoma after Complete Surgical Resection

Autor: Basse, C., Botticella, A., Molina, T.J., Falcoz, P.E., Oulkhouir, Y., Kerjouan, M., Pichon, E., Westeel, V., Thiberville, L., Quantin, X., Clément-Duchêne, C., Khalifa, J., Tinier, F. Le, Ginoux, M., Thillays, F., Mordant, P., Besse, B., Thomas, P.A., Péchoux, C. Le, Girard, Nicolas

Publikováno v: In Clinical Lung Cancer September 2021 22(5):469-472

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

LBA71 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743

Autor: Zalcman, G., Oulkhouir, Y., Cornelissen, R., Greillier, L., Cid, J.R. Rodriguez, Mazieres, J., Briggs, P., Nowak, A.K., Tsao, A., Fujimoto, N., Peters, S., Mansfield, A.S., Popat, S., Nassar, A., Bushong, J., Hu, N., Spires, T., Balli, D., Eccles, L., Baas, P.

Publikováno v: In Annals of Oncology September 2022 33 Supplement 7:S1438-S1439